Elevated serum CCL22 was also linked with improved survival in a cohort of 1208 patients with glioma [32]; however, serum CCL22 was found to be elevated in advanced tumor stages in breast cancer [33] and was associated with metastatic spread and recurrence in gastric cancer patients [34]. Here, CCL22 is linked to gastric cancer.